Shifting the Focus: Anticoagulation in the Older Adult 7/24/2015. Faculty Disclosures
|
|
- Phillip Hutchinson
- 8 years ago
- Views:
Transcription
1 Shifting the Focus: Anticoagulation in the Older Adult Faculty Disclosures Kelechi C. Ogbonna, PharmD, CGP Nothing to disclose Kelechi C. Ogbonna, PharmD, CGP Assistant Professor, Geriatrics Department of Pharmacotherapy & Outcomes Science Virginia Commonwealth University School of Pharmacy Learning Objectives Following this presentation, the participant will be able to: Learning Objectives Following this presentation, the participant will be able to: 1. Compare and contrast the pharmacology, pharmacokinetics, and other attributes of newly released target specific oral anticoagulants (TSOACs) to existing strategies for anticoagulation in atrial fibrillation and venous thromboembolism 2. Identify patient characteristics and clinical scenarios that may dissuade the use of TSOACs 1. When presented with a patient requiring anticoagulation, design a comprehensive and appropriate treatment plan 1. Compare and contrast the pharmacology, pharmacokinetics, and other attributes of newly released target specific oral anticoagulants (TSOACs) to existing strategies for anticoagulation in atrial fibrillation and venous thromboembolism 2. Identify patient characteristics and clinical scenarios that may dissuade the use of TSOACs 1. When presented with a patient requiring anticoagulation, design a comprehensive and appropriate treatment plan Audience Response If you were given the option to select antithrombotic therapy for an older adult, which of the following agents would YOU choose? A. dabigatran B. rivaroxaban C. apixaban D. edoxaban E. warfarin 1
2 Efficacy in Older Adults has been shown to reduce the risk of stroke by 60 70%, including among patients 75 years of age or older Caveat Efficacy depends on maintaining TTR at least 55 60% of the time It s Complicated use is complicated by numerous interactions with other medications, dietary supplements, and food leading to labile INRs Mant J et al. Lancet 2007;370: Connolly SJ et al. Circulation 2008;118: White HD et al. Arch Intern Med. 2007;167: Pharmacogenomic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness Target Vitamin K Metabolism Bioavailability (%) >95 Protein Binding (%) 99 Renal Excretion (%) 0 Interactions Food Vit. K rich foods Cytochrome P450 2C9, 3A4, 1A2 P glycoprotein none Major DDI Amiodarone, TMP SMX, others Pharmacokinetics Half life (h) Time to maximum plasma conc. (h) Variable Geriatric Focus A New Frontier? Efficacy vs. Reality Only 30 60% of NH residents with AF receive warfarin even in the absence of contraindications 20 30% of NH residents receive no antithrombotic at all To Bleed or Not to Bleed Providers tend to overestimate bleeding risk and underestimate the risk of stroke in older adults Abdel Latif AK et al. J Am Med Dir Assoc 2005;6: McCormick D et al. Arch Intern Med. 2001;161: Lau E et al. J Am Geriatr Soc 2004;52: June, 1954 Bill Haley's single "Rock Around the Clock released 1st TV soap opera "Secret Storm" premieres Eisenhower warns against US intervention in Vietnam October, 2010 Lil Wayne s Rebirth album released Season 5 of Keeping Up with the Kardashians begins Obama announces end to Operation Iraqi Freedom Timeline Atrial Fibrillation DVT & PE ximelagatran Intro: 2004* Class: 1 st oral direct thrombin inhibitor Study: EXTEND Removed in 2006 A. Fib dabigatran Recurrence Intro: 2010 Class: Oral direct thrombin inhibitor Study: RE LY rivaroxaban *NDA for ximelagatran submitted in 2004, however was never approved by FDA. This agent was approved in several other countries.. PPX Hip & Knee Intro: 2012 DVT & PE Focus: DVT & PE Class: Factor Xa inhibitor Study: EINSTEIN Program Intro: 2011 Class: Factor Xa inhibitor apixaban Study: Intro: 2012 ROCKET AF edoxaban Intro: 2015 Class: Factor Xa inhibitor Study: ENGAGE TIMI 48 Hokusai VTE studies Class: Factor Xa inhibitor Study: ARISTOTLE Characteristics Rivaroxaban Apixaban Edoxaban Oral Target Antithrombotic Agents Thrombin Factor Xa Factor Xa Factor Xa Metabolism Bioavailability (%) ~50 ~50 Protein Binding (%) ~ Renal Excretion (%) 80 ~ Interactions Food & absorption 2h delay Increased bioavailability None None Cytochrome P450 None Present Present Present P glycoprotein Present Present Present Present Major DDI Rifampin, Ritonavir, Ritonavir, Ritonavir, quinidine ketoconazole ketoconazole ketoconazole Pharmacokinetics Half life (h) Time to maximum plasma conc. (h)
3 Geriatric Focus Rate of Enrollment Median Age [years] >75 years of age Atrial Fibrillation RE LY 71 40% ROCKET AF 73 43% ARISTOTLE 70 31% AVERROES 70* 34% Acute VTE or Pulmonary Embolism EINSTEIN 56 13% EINSTEIN PE 58 18% Extended Treatment of VTE EINSTEIN Extension 58 16% AMPLIFY EXT 57 13% RE MEDY 54 9% Eur J Intern Med Jun;24(4): J Am Geriatr Soc. 2014;62: Finding The Perfect Balance Bleed To cause Stroke To prevent The Debate Miraculous Medications Lower stroke rates Lower bleeding rates Lower mortality rates Less hassle Middle Ground Dangerous Drugs Short half life Lack of monitoring Cannot titrate dose No antidote Drug cost Not enough dataa Learning objectives Following this presentation, the participant will be able to: 1. Compare and contrast the pharmacology, pharmacokinetics, and other attributes of newly released target specific oral anticoagulants (TSOACs) to existing strategies for anticoagulation in atrial fibrillation and venous thromboembolism 2. Identify patient characteristics and clinical scenarios that may dissuade the use of TSOACs 1. When presented with an patient requiring anticoagulation, design a comprehensive and appropriate treatment plan High Risk Patients Renal Impairment Study Intervention Control Design Exclusion RELY RE MEDY ROCKET AF EINSTEIN Investigators EINSTEIN PE Investigators 110mg or mg mg Rivaroxaban 20mg daily or 15mg daily Rivaroxaban 15mg for 3 wks, then 20mg daily Rivaroxaban 15mg for 3 wks, then 20mg daily Enoxaparin daily 5 doses, followed by therapeutic VKA Enoxaparin daily 5 doses, followed by therapeutic VKA NVAF DVT or PE NVAF symptomatic DVT symptomatic PE Morill et al. Ann Pharmacother Jun 23. [Epub ahead of print] 3
4 Study Intervention Control Design Exclusion ARISTOTLE AVERROES Lassen et al Hokusai VTE Investigators ENGAGE AF TIMI 48 Investigators Apixaban 5mg or 2.5mg Apixaban 5mg or 2.5mg Apixaban 2.5mg Edoxaban 60mg daily or 30mg daily Edoxaban 60mg daily or 30mg daily ASA mg daily Enoxaparin 40mg q12h NVAF Superiority NVAF DVT, PE, Mortality symptomatic VTE NVAF CrCL<25mL/min, SCr >2.5mg/dL CrCL<25mL/min, SCr >2.5mg/dL Significant renal impairment Rivaroxaban PK/PD study: AUC PK/PD study: In levels found to be 1.5, patients with CrCl of 3.2, and 6.3 fold higher ml/min,15mg in subjects with mild, dose achieved an AUC moderate and severe similar to a 20mg dose renal impairment in patients with normal Excretion time: renal 24 h function vs.96 h for patients with severe renal impairment Edoxaban Apixaban PK/PD study: In PK/PD study: Systemic patients with CrCl of exposure increases by ml/min a 43% 57%, 35%, and 11.6% increase in apixaban in patients with CrCl of exposure is expected 30, 50, and 80 ml/min, when compared to respectively, when patients without renal compared to patients impairment without renal impairment Morill et al. Ann Pharmacother Jun 23. [Epub ahead of print] Clin Pharmacokinet. 2010;49(4): Clin Pharmacokinet. 2011;50(10): Clin Pharmacol Ther. 2010;88(3): J Clin Pharmacol May 12. [Epub ahead of print] Several case reports have been sited describing negative outcomes with dabigatran in patients with renal impairment Nonvalvular A.Fib 50 ml/min ml/min ml/min <15 ml/min mg mg A 75mg Avoid Rivaroxaban 20mg daily 15mg daily 15mg daily Avoid Apixaban 5mg * 2.5mg * 2.5mg * Contraindicated Edoxaban 60mg daily 30mg daily 30mg daily Avoid A dose adjustment not recommended unless patient receiving dronedarone or ketoconazole *Apixaban should be dose reduced to 2.5mg for patient with SCr >1.5 mg/dl DVT/PE 50 ml/min ml/min ml/min <15 ml/min mg mg A Avoid Rivaroxaban 20mg daily 15mg daily Avoid Avoid Apixaban 5mg * 5mg * 5mg * Avoid Edoxaban 60mg daily 30mg daily 30mg daily Avoid Age(y) /Sex Weight (Kg) CrCl 66/F /M /F /F /F Dose (mg) Therapy duration (Months) Ann Pharmacother Jul Aug;46(7 8): Bleeding Event Plasma Conc. (ng/ml) 2 Upper GI bleed NR Retroperiton eal, GI, and pleural hemorrhage Rectal/Lower GI bleeding Recurrent epistaxis x 1 wk 280 NR Outcome D/C d Aggressive interventions D/C d Pericardiocentesis D/C d Nasal cauterization The two case reports below highlight the importance of renal dose adjustments and careful patient selection. Clinicians should also provide appropriate monitoring beyond the initial visit. As noted below adverse outcomes vary in their onset. Age(y) /Sex Weight (Kg) CrCl 66/F /M /F /F /F Dose (mg) Therapy duration (Months) Ann Pharmacother Jul Aug;46(7 8): Bleeding Event Plasma Conc. (ng/ml) 2 Upper GI bleed NR Retroperiton eal, GI, and pleural hemorrhage Rectal/Lower GI bleeding Recurrent epistaxis x 1 wk 280 NR Outcome D/C d Aggressive interventions D/C d Pericardiocentesis D/C d Nasal cauterization Age(y) /Sex Weight (Kg) CrCl 66/F /M /F /F /F Dose (mg) Therapy duration (Months) Ann Pharmacother Jul Aug;46(7 8): Bleeding Event Plasma Conc. (ng/ml) 2 Upper GI bleed NR Hemopericardium Hemopericardium Hemopericardium Retroperiton eal, GI, and pleural hemorrhage Rectal/Lower GI bleeding Recurrent epistaxis x 1 wk 280 NR Outcome D/C d Aggressive interventions D/C d Pericardiocentesis D/C d Nasal cauterization 4
5 If a patient has a CrCl < 15ml/min which TSOAC represents the best option? If a patient has a CrCl < 15ml/min which TSOAC represents the best option? a) a) b) Rivaroxaban c) Apixaban d) Edoxaban e) b) Rivaroxaban c) Apixaban d) Edoxaban e) None of the TSOACs are recommended for use in patients with a CrCl < 15mL/min High Risk Patients Clinical Application In the setting of renal impairment consider the following: 1 Ability to obtain baseline and routine serum creatinine levels 2 Degree of renal impairment 3 Reassess patients eligibility for warfarin therapy Frailty & Low Body Weight *Important* - Edoxaban: If CrCl >95mL/min DO NOT USE - risk of stroke observed in clinical trials Frailty & Body Weight - RE LY: Average weight = 82.5 kg or lbs Trough concentrations approx. 20% lower in patients >100 kg Limited data on patients < 50 kg - ROCKET AF: Average weight = 82.1 kg or lbs Cmax increased by approx. 24% in subjects weighing 50 kg, resulting in a small (15%) increase in prolongation of prothrombin time Patients 120kg unaffected - ARISTOTLE: Average weight = 82 kg or lbs AUC 20% higher in patient 50kg and 23% lower in patients 120kg - ENGAGE AF TIMI 48: Average weight = 84 kg or 185 lbs There is a limited amount of clinical data incorporating patients with body weight extremes. However, pharmacokinetic findings point to changes in drug concentrations in patients with extremely low or high body weights. Increase Exposure for patient 60kg [change in AUC not defined] Body Weight Clinical Application Patient characteristics and drug attributes should drive decision making. Body weight extremes may effect drug kinetics and should be taken into account when prescribing a TSOAC. The inability to titrate these medications and readily monitor a therapeutic index makes use in patients with body weight extremes challenging. Remember to dose adjust edoxaban and apixaban 1 Edoxaban & DVT/PE: Patient weight 60 kg 30 mg once daily 2 Apixaban: Patient weight 60 kg 2.5 mg twice daily Br J Clin Pharmacol Mar 14 Postgrad Med Jan;125(1):34 44 Drugs. 2014; 74(11):
6 High Risk Patients Bleeding risk is often the predominant factor that dictates anticoagulant therapy in older adults. Bleeding Expressed as RRR (%) 110mg RE LY ROCKET AF ARISTOTLE ENGAGE AF mg Rivaroxaban Apixaban Edoxaban Primary Outcome 10* 35* 21* 21* 21* Hemorrhagic Stroke 69* 74* 41* 49* 46* Ischemic/Unkno wn Stroke 11 24* 6 8 Major Bleed 20* * 20* Intracranial Hemorrhage** 70* 59* 33* 58* 53* GI Bleed 8 48* 46* 11 23* All death * 8* *P < Thrombosis. 2012;2012:1 **In modified intention to treat analysis, statistical significance was not reported Epub 2012 Sep 10 #Comparison using reported raw event frequencies, as annualized event rates were unavailable Expressed as RRR (%) 110mg The risk of intracranial hemorrhage appears to be much improved with the TSOACs, noted by the statistically significant RRR across trials. RE LY ROCKET AF ARISTOTLE ENGAGE AF mg Rivaroxaban Apixaban Edoxaban Primary Outcome 10* 35* 21* 21* 21* Hemorrhagic Stroke 69* 74* 41* 49* 46* Ischemic/Unkno wn Stroke 11 24* 6 8 Major Bleed 20* * 20* Intracranial Hemorrhage** 70* 59* 33* 58* 53* GI Bleed 8 48* 46* 11 23* All death * 8* *P < RRR = Relative Risk Reduction Thrombosis. 2012;2012: **In modified intention to treat analysis, statistical significance was not reported. #Comparison using reported raw event frequencies, as annualized event rates were unavailable Expressed as RRR (%) 110mg GI bleeding was increased when compared to warfarin with dabigatran mg and rivaroxaban. As discussed before this same trend has been observed in clinical practice RE LY ROCKET AF ARISTOTLE ENGAGE AF mg Rivaroxaban Apixaban Edoxaban Primary Outcome 10* 35* 21* 21* 21* Hemorrhagic Stroke 69* 74* 41* 49* 46* Ischemic/Unkno wn Stroke 11 24* 6 8 Major Bleed 20* * 20* Intracranial Hemorrhage** 70* 59* 33* 58* 53* GI Bleed 8 48* 46* 11 23* All death * 8* *P < RRR = Relative Risk Reduction Thrombosis. 2012;2012: **In modified intention to treat analysis, statistical significance was not reported. #Comparison using reported raw event frequencies, as annualized event rates were unavailable Apixaban is the only TSOAC that has been shown to reduce the risk of mortality. Expressed as RRR (%) 110mg RE LY ROCKET AF ARISTOTLE ENGAGE AF mg Rivaroxaban Apixaban Edoxaban Primary Outcome 10* 35* 21* 21* 21* Hemorrhagic Stroke 69* 74* 41* 49* 46* Ischemic/Unkno wn Stroke 11 24* 6 8 Major Bleed 20* * 20* Intracranial Hemorrhage** 70* 59* 33* 58* 53* GI Bleed 8 48* 46* 11 23* All death * 8 *P < RRR = Relative Risk Reduction Thrombosis. 2012;2012: **In modified intention to treat analysis, statistical significance was not reported. #Comparison using reported raw event frequencies, as annualized event rates were unavailable J Am Geriatr Soc. 2014;62:
7 Clinical Application - Bleeding with any anticoagulant will always be a concern. That being said, reviewing drug and patient characteristics may dissuade the use of one agent over another., rivaroxaban, and edoxaban associatied with GI bleeding. Caution in patients with history of GI bleeding or conditions that predispose them to GI bleeding (e.g. peptic ulcer disorder). Intracranial hemorrhage (ICH) is the most feared and lethal complication of oral anticoagulation. The reduction in ICH with the TSOACs is a major benefit. Providers will need to determine if this benefit outweighs added risk in other areas. TSOAC reduce the risk of when compared to warfarin. a) Intracranial hemorrhage b) Ischemic stroke c) Mortality d) All of the above Careful Consideration TSOAC reduce the risk of when compared to warfarin. a) Intracranial hemorrhage b) Ischemic stroke c) Mortality d) All of the above Conversion Conversion Considerations From/To From warfarin Agent Corresponding INR INR < 2 Rivaroxaban INR < 3 Apixaban INR < 2 Edoxaban INR 2.5 To warfarin Rivaroxaban, Apixaban, and Edoxaban: - Discontinue TSOAC and begin both a parenteral anticoagulant and warfarin at the time the next dose of TSOAC would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range. Careful Consideration Adherence Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Eliquis [package insert]. Princton, NJ: Bristol Myers Squibb Company; Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; Savaysa [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc., Inc;
8 Adherence Clinical Application - Adherence to TSOAC therapy remains a concern Although not ideal, warfarin s mechanism of action and dependence on the depletion of clotting factors provides a buffer period should a patient miss a dose TSOAC s relatively short half life leaves little room for error. Unlike warfarin, without routine monitoring identifying non adherent patients will require scrutiny of refill histories and direct patient questioning. It remains unknown how periods of non adherence with the TSOAC may affect outcomes. Providers should use discretion when prescribing TSOAC, particularly in the setting of patient adherence, and ensure patients are aware of the risks. Adherence Patient Counseling -, Apixaban, & Edoxaban If a dose is missed, take a dose as soon as possible on the same day. The dose should be skipped if it can not be taken at least 6 hours before the next scheduled dose The dose should not be doubled to make up for a missed dose. - Rivaroxaban If a dose is missed take a dose as soon as possible as follows: For patients receiving 15mg Take 2 tablets (30mg) at once and resume 15mg the following day For patients receiving 20mg, 15mg, or 10mg once daily Take the missed dose immediately Careful Consideration Drug Drug Interactions Rivaroxaban Apixaban Edoxaban Interactions Cytochrome P450 None Present Present Present P glycoprotein Present Present Present Present Moderate to strong PGP inhibitors have the potential to increase serum concentrations of dabigatran, rivaroxaban, and apixaban. Strong to Moderate PGP Inhibitors Verapamil Quinidine Amiodarone Ketoconazole Itraconazole Ritonavir Nelfinavir saquinavir Tacrolimus Cyclosporine Am J Hematol. 2011;86: , J Thromb Thrombolysis. 2010;29(1): , Ann Pharmacother. 2011; 45: Strong CYP3A4 inhibitors have the potential to increase serum concentrations of dabigatran, rivaroxaban, and apixaban. Evaluating TSOACs in conjunction with dual antiplatelet therapy Strong to Moderate CYP 3A4 Inhibitors Clarithromycin Ketoconazole Itraconazole Atazanavir Lopinavir Ritonavir Of the CYP enzymes, CYP3A4 is not only the most prevalent CYP enzyme in the liver, but is used by more than 50% of medications on the market. Rivaroxaban Apixaban Edoxaban Interactions Cytochrome P450 None Present Present Present P glycoprotein Present Present Present Present Am J Hematol. 2011;86: , J Thromb Thrombolysis. 2010;29(1): , Ann Pharmacother. 2011; 45: Tsu LV et al. Ann Pharmacother 2013;47:
9 Synopsis: 5 randomized controlled trials have evaluated the safety and efficacy of using therapeutic doses of dabigatran, rivaroxaban, and apixaban in conjunction with dual antiplatelet therapy Results: Increases risk of major and clinically relevant nonmajor bleeding with triple therapy Tsu LV et al. Ann Pharmacother 2013;47: RE LY: Did not exclude dual antiplatelet therapy Only 40% of the population received aspirin therapy Only 5% of the population received clopidogrel therapy ROCKET AF: Excluded the use of aspirin >100mg Excluded the concomitant use of aspirin and clopidogrel ARISTOTLE: Excluded the use of aspirin >165mg Excluded the concomitant use of aspirin and clopidogrel ENGAGE AF: Did not exclude dual antiplatelet therapy Only 29% of the population received aspirin therapy Ann Pharmacother 2013;47: Clinical Application - The TSOACs are not devoid of drug drug interactions. Providers must once again weigh the benefits and risks of concomitant therapy PGP Inhibitors/Inducers: All of the TSOACs are effected by changes in the P glycoprotein efflux pump. and edoxaban are the most effected TSOACs and caution should be exercised when administration with a known inhibitor or inducer CYP3A4 Inhibitors/Inducers: As stated previously, CYP3A4 is the most prevalent CYP enzyme in the liver. Rivaroxaban, apixaban, and edoxaban s dependence on CYP3A4 for metabolism is a disadvantage. Providers should be mindful of this interaction when prescribing or managing these medications Clinical Application - Dual Antiplatelet Therapy Triple therapy leads to clinically relevant bleeding. In addition, the landmark trials that garnered FDA approval either excluded patients on ASA >165mg or had a very small proportion of patients on an antiplatelet drug. Providers should avoid triple therapy with the TSOAC until proven safe and effective Careful Consideration Monitoring Monitoring Monitoring - The TSOACs, in general, have predictable pharmacokinetics, pharmacodynamics, and metabolism. However, this predictability is sometimes lost when treating older adults as these parameters change with aging. At this point in time routine LABORATORY monitoring is NOT recommended and has not been correlated to clinical outcomes Coagulation test should be interpreted with caution Coagulation test results are mostly helpful as qualitative assessment only (e.g. determining if an anticoagulant is present or absent) 9
10 Monitoring Monitoring - There are scenarios where TSOAC measurement may be desirable, such as: Surgery or invasive procedures Hemorrhagic or thrombotic event Suspected drug failure Suspected overdose Extremes of age Assess adherence Extremes of weight Declining renal function Need for thrombolytics - Important: Standard anti factor Xa levels cannot be used to measure the effects of rivaroxaban and apixaban. An assay specific to each drug must be used Lab Test Rivaroxaban/apixaban/edoxaban PT/INR aptt TT (thrombin time) ECT (ecarin clotting time) Should not use (poor sensitivity) Normal aptt suggests minimal anticoagulant activity Normal TT excludes presence of significant levels Normal ECT excludes presence of significant levels Normal INR (+ normal aptt) suggests minimal anticoagulant activity Normal aptt (+ normal INR) suggests minimal anticoagulant activity Do not use Do not use Chromogenic assays Unavailable for anti IIa Normal anti Xa assay excludes presence of significant rivaroxaban or apixaban level dpt (diulute PT) Role still unclear (promising) Role still unclear (promising) Heptest PICT (prothrombinase induced clotting time) Am J Health Syst Pharm. 2012(69):e28 e39. Do not use Unknown Normal suggests minimal anticoagulant activity Normal suggests minimal anticoagulant activity Careful Consideration Reversal Which of the following agents can be used to reverse the effect of dabigatran, rivaroxaban, or apixaban? a) Vitamin K b) Prothrombin complex concentrate c) Factor VII d) None of the above Which of the following agents can be used to reverse the effect of dabigatran, rivaroxaban, or apixaban? a) Vitamin K b) Prothrombin complex concentrate c) Factor VII d) None of the above At this time, an antidote does not exists for the TSOACs Reversal Strategies Reversal - Unlike warfarin, there is no reversal agent for dabigatran, rivaroxaban, apixaban, or edoxaban. Management of life threatening bleeds remains empirical and anecdotal. 1 Hemodialysis HD removes ~62% of dabigatran in 2 hours Not an option for rivaroxaban or apixaban given protein binding 2 Activated Charcoal May be helpful if administered within 1 to 2 hours of acute overdose 3 Supportive care most likely option in clinical practice Early volume and RBS repletion Recombinant factor VII or PCC J Cardiovasc Electrophysiol.2011(22):
11 Reversal Strategies Emerging Therapies 1 Andexant Developed by Portola Pharmaceuticals, Inc. Recombinant molecule that is a direct reversal agent for factor Xa inhibitors Single IV bolus February 2015 Received orphan drug status from the FDA 2 Idarucizumab Developed by Boehringer Ingelheim Humanized antibody fragment that binds directly to dabigatran Two bolus infusions given <15 minutes apart March 2015 Received orphan drug status from the FDA 3 Aripazine Developed by PerosphereTM Pollack CV, et al. NEJM. 2015(June 22).[Epub ahead of print]. Ansell JE, et al. NEJM. 2015; 371(22): Lu G, et al. Nat Med. 2013; 19(4): Synthetic small molecule effective against ALL anticoagulants (except warfarin) Single IV bolus Summary Matching Patient Characteristics Mechanical valve or valvular A.Fib Rivaroxaban Apixaban Edoxaban Labile INRs CrCl ml/min CrCl <30 ml/min Child Pugh B or C Dual Antiplatelet GI Bleeding Swallowing Difficulty Shifting the Focus: Anticoagulation in the Elderly Case Discussion 11
DABIGATRAN ETEXILATE TARGET Vitamin K epoxide reductase WARFARIN RIVAROXABAN APIXABAN
TARGET SPECIFIC ORAL ANTICOAGULANTS (TSOACs) This document is intended as a guideline only and should not replace sound clinical judgment Please refer to UNMH formulary in Lexicomp for approved use(s)
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationFDA Approved Oral Anticoagulants
FDA Approved Oral Anticoagulants Generic (Trade Name) Warfarin (Coumadin, Jantoven ) 1 FDA approved indication Prophylaxis and treatment of venous thromboembolism (VTE) Prophylaxis and treatment of thromboembolic
More informationDVT/PE Management with Rivaroxaban (Xarelto)
DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular
More informationObjectives. New and Emerging Anticoagulants. Objectives (continued) 2/18/2014. Development of New Anticoagulants
Objectives New and Emerging Anticoagulants Adraine Lyles, PharmD, BCPS Clinical Pharmacy Specialist VCU Medical Center Describe the pharmacology of the novel oral anticoagulants Discuss the clinical evidence
More informationDisclosure/Conflict of Interest
NEW ORAL ANTICOAGULANTS: WHAT EVERY PHARMACIST SHOULD KNOW LORI B. HORNSBY, PHARMD, BCPS ASSOCIATE CLINICAL PROFESSOR AUHSOP CLINICAL PHARMACIST MIDTOWN MEDICAL CENTER OUTPATIENT CLINIC COLUMBUS, GEORGIA
More information48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.
48 th Annual Meeting Terminology Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding Stacy A. Voils, PharmD, MS, BCPS Navigating the Oceans of Opportunity Target-specific oral anticoagulants
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationDOACs. What s in a name? or TSOACs. Blood Clot. Darra Cover, Pharm D. Clot Formation DOACs work here. Direct Oral AntiCoagulant
DOACs NOACs or TSOACs Generic Name DOACs Brand Name Mechanism of Action Direct Xa Inhibitor Direct Thrombin Inhibitor Dabigatran Pradaxa X Rivaroxaban Xarelto X Darra Cover, Pharm D Apixaban Eliquis X
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationTSOAC Initiation Checklist
Task Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function. Evaluate for medication interactions that may necessitate TSOAC dose adjustment.
More informationNEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM
NEWER ANTICOAGULANTS: FOCUS ON STROKE PREVENTION IN ATRIAL FIBRILLATION AND DEEP VEIN THROMBOSIS/PULMONARY EMBOLISM Carol Lee, Pharm.D., Jessica C. Song, M.A., Pharm.D. INTRODUCTION For many years, warfarin
More informationNovel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015
Novel Anticoagulation Agents DISCLOSURES James W. Haynes, MD Department of Family Medicine Univ of TN Health Science Center (Chattanooga) Objectives Understand mechanism of action behind the NOAC agents
More informationHow To Understand The History Of Analgesic Drugs
New Developments in Oral Anticoagulants: Treating and Preventing Embolic Events in the 21 st Century David Stewart, PharmD, BCPS Associate Professor of Pharmacy Practice East Tennessee State University
More informationHow To Compare The New Oral Anticoagulants
Disclosures The New Oral Anticoagulants: Are they better than Warfarin? Alan P. Agins, Ph.D. does not have any actual or potential conflicts of interest in relation to this CE activity. Alan Agins, Ph.D.
More informationFailure or significant adverse effects to all of the alternatives: Eliquis and Xarelto
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics
More informationVenous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.
Venous Thromboembolism: Long Term Anticoagulation Dan Johnson, Pharm.D. Disclosures No financial relationships with products discussed Off-label use of drug therapy always discussed Objectives Review clinical
More informationThe Role of the Newer Anticoagulants
The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention
More informationClinical Assistant Professor University of Kansas School of Pharmacy. Objectives
New Oral Anticoagulants Tiffany R. Shin, PharmD, BCACP Clinical Assistant Professor University of Kansas School of Pharmacy 1 Objectives Discuss the advantages and disadvantages of the new oral anticoagulants
More informationCardiovascular Disease
Cardiovascular Disease 1 Cardiovascular Disease 1. More target specific oral anticoagulants (TSOAC) 2. Vorapaxar (Zonivity) 3. Continued noise about a polypill 4. WATCHMAN 3 1 2 3 4 Left Atrial Appendage
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationDabigatran (Pradaxa) Guidelines
Dabigatran (Pradaxa) Guidelines Dabigatran is a new anticoagulant for reducing the risk of stroke in patients with atrial fibrillation. Dabigatran is a direct thrombin inhibitor, similar to warfarin, without
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationReversing the New Anticoagulants
Reversing the New Anticoagulants Disclosure Susan C. Lambe, MD Assistant Clinical Professor Department of Emergency Medicine University of California, San Francisco Roadmap for today 1 Roadmap for today
More information5/21/2012. Perioperative Use Issues. On admission: During hospitalization:
Dabigatran and Rivaroxaban: Challenges in the Perioperative Setting Claudia Swenson, Pharm.D., CDE, BC-ADM, FASHP Central Washington Hospital Wenatchee, WA claudia.swenson@cwhs.com Dabigatran and Rivaroxaban:
More informationDisclosures. I have served as an advisory board member, consultant, speaker, and / or received research funding from: Sanofi-Aventis
TSOACs: Glee Lenoir, Pharm D. Pharmacy Clinical Coordinator The Medical Center Nursing Conference March 2015 Disclosures I have served as an advisory board member, consultant, speaker, and / or received
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationGuideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis )
Guideline for the Prescribing of Novel Oral Anticoagulants (NOACs): Dabigatran (Pradaxa ), Rivaroxaban (Xarelto ), Apixaban (Eliquis ) The contents of this CPG are to be used as a guide. Healthcare professionals
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationOut with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation
Out with the Old and in with the New? Target Specific Anticoagulants for Atrial Fibrillation Goal Statement Pharmacists and technicians will gain knowledge in the use of target specific oral anticoagulants
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Service Ansell, J. Hematology Copyright 2010 American Society of Hematology.
More information1/7/2012. Objectives. Epidemiology of Atrial Fibrillation(AF) Stroke in AF. Stroke Risk Stratification in AF
Objectives Atrial Fibrillation and Prevention of Thrombotic Complications: Therapeutic Update Andrea C. Flores Pharm.D Pharmacy Resident at the Miami VA Healthcare System Review the epidemiology, pathophysiology
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationCardiology Update 2014
Cardiology Update 2014 Update on the Novel Oral Anticoagulants (NOACS) Raymond Kawasaki, MD AMG Cardiology December 6, 2014 Disclosures I have no disclosures relevant to this presentation Contents I. The
More informationAnticoagulants. Denver Health April 12, 2011
New Oral Anticoagulants Rebecca Hanratty, MD Denver Health April 12, 2011 Overview Why we need alternatives to warfarin Review of the 3 new oral anticoagulants Results from major trials: Thromboprophylaxis
More informationExperience matters: Practical management in your hospital
Experience matters: Practical management in your hospital Dr AGG Turpie McMaster University, Hamilton, ON, Canada Disclosures AGG Turpie has acted as a consultant for Bayer HealthCare, Janssen, Sanofi-Aventis,
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE June 22, 2015 SUBJECT EFFECTIVE DATE MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants Pharmacy Service Leesa M. Allen, Deputy Secretary Office of Medical
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationNovel Oral Anticoagulants (NOACs) Prescriber Update 2013
Novel Oral Anticoagulants (NOACs) Prescriber Update 2013 Indications/Contraindications Indications Orthopedic VTE Prophylaxis VTE Treatment Stroke Prevention for non-valvular AF Contraindications 150 mg
More informationBreadth of indications matters One drug for multiple indications
Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants which meet any of the following conditions
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below
Name: generic (trade) Rivaroxaban (Xarelto ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RIVAROXABAN RECOMMENDED see specific recommendations for licensed indications below What it is Indications
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationNew Oral Anticoagulant Drugs What monitoring if any is required?
New Oral Anticoagulant Drugs What monitoring if any is required? Michelle Williamson Supervising Scientist High Throughput Haematology Pathology Queensland PAH Laboratory Overview Background What new oral
More informationStop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery
Stop the Bleeding: Management of Drug-induced Coagulopathy Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery Objectives Discuss contemporary management of warfarin reversal in patients
More informationAHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation
AHA/ASA Scientific Statement Oral Antithrombotic Agents for the Prevention of Stroke in Atrial Fibrillation A Statement for Healthcare Professionals from the American Heart Association/American Stroke
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More information1/12/2016. What s in a name? What s in a name? NO.Anti-Coagulation. DOACs in clinical practice. Practical aspects of using
What s in a name? Practical aspects of using DOACs (Direct Oral Anticoagulants) James L. Sebastian, MD, MACP Professor of Medicine (GIM) Medical College of Wisconsin February 5, 2016 DOAC NOAC NOAC ODI
More informationNew Anticoagulation Agents and Their Reversal Agents. Objectives. Background 12/21/2015
New Anticoagulation Agents and Their Reversal Agents Jay Hazelcorn, Pharm.D. PGY-1 Pharmacy Resident Broward Health Medical Center Objectives Review the pharmacology, indications, and place in therapy
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationTimeline: FDA approval of NOACs. FDA-approved oral anticoagulants. FDA-approved oral anticoagulants. Stroke risk reductions: afib RCTs 4/8/2016
Christina York, PharmD, BCPS Pharmacology Conference April 2016 Objectives Compare current FDA-approved oral anticoagulants Understand practical issues that arise with novel oral anticoagulants Consider
More informationLearning Objectives Novel Oral Anticoagulants in the Geriatric Patient: To Bleed or Not to Bleed
Learning Objectives Novel Oral Anticoagulants in the Geriatric Patient: To Bleed or Not to Bleed Jonathan D. Edwards, Pharm.D., BCPS, CGP Huntsville Hospital Department of Pharmacy Huntsville, Alabama
More informationPost-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師
Post-ISTH review: Thrombosis-I New Oral Anticoagulants 臺 大 醫 院 內 科 部 血 液 科 周 聖 傑 醫 師 The antithrombotic efficacy is limited but the risk of bleeding is indefinite Fuster V et al. Circulation 2011;123:e269-e367
More informationEfficacy in Hip Arthroplasty. Efficacy in Knee Arthroplasty. Adverse Effects. Drug Interactions
Objectives Just for the RECORD: Rivaroxaban joins the US Anticoagulation Arsenal Anne P. Spencer, PharmD, FCCP, BCPS (AQ Cardiology) Cardiovascular Care Pharmacy Specialist Roper Saint Francis Healthcare
More informationAnticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014
Anticoagulation: How Do I Pick From All the Choices? Jeffrey H. Neuhauser, DO, FACC BHHI Primary Care Symposium February 28, 2014 Atrial Fibrillation 2 Atrial Fibrillation The most common arrhythmia encountered
More informationNon- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose. Warfarin vs the NOACs
Non- Valvular Atrial Fibrillation and Stroke Prevention: Which OAC Do I Choose Warfarin vs the NOACs Dr. Lori McIntosh D.O. Board Certified Neurologist Objectives Be able to list the current options of
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationNew Oral AntiCoagulants (NOAC) in 2015
New Oral AntiCoagulants (NOAC) in 2015 William R. Hiatt, MD Professor of Medicine and Cardiology University of Colorado School of Medicine President CPC Clinical Research Disclosures Received research
More information2/17/2015 ANTICOAGULATION UPDATE OBJECTIVES BRIEF REVIEW: CLASSES OF ORAL ANTICOAGULANTS
ANTICOAGULATION UPDATE C AR R I E P AL M E R, D N P, RN, AN P - BC OBJECTIVES At the end of the presentation, the NP will be able to: Identify new indications for target-specific oral anticoagulants (TSOACs),
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationWarfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab
Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 28, 2015 2:30 pm I have no disclosures. Stroke risk reduction in
More informationPrescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients
Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as
More informationOral Anticoagulation in Older Persons The Next Generation
Oral Anticoagulation in Older Persons The Next Generation Luis Viana B.Sc. Phm., Pharm D (candidate), M.Ed., ACPR, CGP Clinical Consultant Pharmacist, Medical Pharmacies Group Limited Adjunct Clinical
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationThe New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012. Jeff Healey
The New Anticoagulants are Here! Do you know how to use them? Arrhythmia Winter School February 11 th, 2012 Jeff Healey RELY: A New Era in AF Connolly SJ et al. N Engl J Med 2009;361:1139-1151 ROCKET-AF:
More informationhttp://www.medscape.org/viewarticle/808338_print
Page 1 of 18 From Medscape Education Cardiology Pharmacokinetics of Anticoagulants: Why It Matters Matthew A. Cavender, MD, MPH; Robert P. Giugliano, MD, SM CME Released: 07/31/2013 ; Valid for credit
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationDisclosures. Objectives 4/25/2014. Novel Anticoagulants in the Elderly
Novel Anticoagulants in the Elderly Bahar Matusik, PharmD, BCPS Assistant Professor Department of Pharmacy Practice & Administration University of Saint Joseph, School of Pharmacy Disclosures Dr. Bahar
More information9/28/15. Dabigatran. Rivaroxaban. Apixaban. Edoxaban. From the AC Forum Centers of Excellence website: Dabigatran, Rivaroxaban, & Apixaban
Identify the FDA approved direct oral anticoagulants (DOACs) Linda Kelly, PharmD, PhC, CACP Presbyterian Healthcare Services Distinguish the differences in the dosing of DOACs for various indications Describe
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationCOMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS. TARGET AUDIENCE: All Canadian health care professionals.
COMPARISON OF NEW ORAL ANTICOAGULANTS AND FREQUENTLY- ASKED QUESTIONS FROM PATIENTS AND PHYSICIANS TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVES: To provide a comparison of the new
More informationMonitoring of new oral anticoagulants
Monitoring of new oral anticoagulants Jonathan Douxfils, Bernard Chatelain September 27th, 2012 1 Content Introduction Monitoring of NOACs Why? Dabigatran etexilate PD properties PK properties Rivaroxaban
More informationAdherence to NOACs. Disclosure. Patricia van den Bemt EAHP Hamburg 2015
Adherence to NOACs Patricia van den Bemt EAHP Hamburg 2015 Disclosure Unrestricted research grants from Glaxo-SmithKline Boehringer Ingelheim Daiichi Sankyo Bayer Pfizer For research on medication safety
More informationDisclosure: Dr. Smith has no actual or potential conflict of interest associated with this presentation.
Disclosure: Dr. Smith has no actual or potential conflict of interest associated with this presentation. Michael Smith, Pharm. D., BCPS, CACP Pharmacy Clinical Manager William Backus Hospital You were
More informationA PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS
A PRACTICAL REVIEW OF THE NOVEL ORAL ANTICOAGULANTS BRIAN CRYDER, PHARMD BCACP LEARNING OBJECTIVES AS A RESULT OF THIS PRESENTATION, THE AUDIENCE WILL BE ABLE TO 1. DISCUSS THE KEY DIFFERENCES BETWEEN
More informationAnticoagulation in Atrial Fibrillation
Anticoagulation in Atrial Fibrillation Parag P. Patel, MD FACC Disclosures Eliquis Speakers Bureau 1 Clinical Scenario Ms. L is a 76F admitted to the stroke service with a dense right sided hemiparesis
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationDISCLOSURES CONFLICT CATEGORY. No conflict of interest to disclose
DISCLOSURES CATEGORY Employment Research support Scientific advisory board Consultancy Speakers bureau Major stockholder Patents Honoraria Travel support Other CONFLICT No conflict of interest to disclose
More informationSTARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach
STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach Jeffrey I Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationNovel OACs: How should we use them?"
Novel OACs: How should we use them?" Iqwal Mangat, MD FRCPC" Director, Arrhythmia Service, St. Michaelʼs Hospital" Assistant Professor of Medicine, University of Toronto" Presenter Disclosure Dr. Iqwal
More informationOral Anticoagulants: What s New?
Oral Anticoagulants: What s New? Sallie Young, Pharm.D., BCPS (AQ-Cardiology) Clinical Pharmacy Specialist, Cardiology Penn State Hershey Medical Center syoung1@hmc.psu.edu August 2012 Oral Anticoagulant
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationNnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl
NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl Mikele Wissing, RN June 2014 Introduction until recently, was the unrivaled medication for treatment
More informationComparative Anticoagulation
Comparative Anticoagulation Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at Austin College of Pharmacy The University of Texas Health Science Center Pharmacotherapy
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationNew Oral Anticoagulants: Thinning out the competition
New Oral Anticoagulants: Thinning out the competition Ashlee D. Gerfen, Pharm.D. University of Arizona Medical Center PGY2 Critical Care Pharmacy Resident DISCLOSURE I have no financial interest, arrangement,
More informationThree new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008:
Key Points to consider when prescribing NOACs Introduction Three new/novel oral anticoagulants (NOAC) have been licensed in Ireland since 2008: Dabigatran Etexilate (Pradaxa ) 75mg, 110mg, 150mg. Rivaroxaban
More informationNHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS
NHS FORTH VALLEY RIVAROXABAN AS TREATMENT FOR DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM IN ADULTS Date of First Issue 01/12/ 2012 Approved 15/11/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More information10/11/2014. Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014
Laura C. Halder, Pharm.D. Postgraduate Year Two Pharmacy Resident Cardiology Abbott Northwestern Hospital Allina Health October 30, 2014 1 1. List two major changes to the 2013 cholesterol treatment guidelines.
More informationMore information for patients and caregivers can be accessed at http://www.xarelto-us.com/.
Janssen Research & Development Submits Application to U.S. FDA for XARELTO (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome RARITAN, DECEMBER 29, 2011 -
More informationImpact of new (direct) oral anticoagulants in patient blood management
Impact of new (direct) oral anticoagulants in patient blood management Yulia Lin, MD, FRCPC, CTBS Transfusion Medicine & Hematology, Sunnybrook Health Sciences Centre Dept of Laboratory Medicine & Pathobiology,
More information